{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:26:48Z","timestamp":1782588408684,"version":"3.54.5"},"reference-count":50,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite the promising antilymphoma activity of histone deacetylase (HDAC) inhibitors as a drug class, resistance is a significant clinical issue. Elucidating the molecular mechanisms driving HDAC inhibitor resistance and\/or the specific targets that are altered in drug-resistant cells may facilitate the development of strategies that overcome drug resistance and are more effective for refractory patients. We generated novel T-cell lymphoma (TCL) cell line models of acquired resistance to the HDAC inhibitor belinostat to identify potential effective therapies. Belinostat-resistant cells displayed significant cross-resistance to other HDAC inhibitors including romidepsin, panobinostat, and vorinostat. Consistent with a lack of sensitivity to HDAC inhibitors, the resistant cells failed to induce increased acetylated histones. Drug-resistant cells featured significantly decreased expression of the key antiviral mediators IRF1 and STAT1. On the basis of these findings, we investigated the efficacy of the clinical formulation of reovirus (Reolysin) in parental and drug-resistant models. Our investigation revealed that HDAC inhibitor\u2013resistant cells displayed enhanced vulnerability to reovirus replication and cell death in both in vitro and in vivo models compared with their parental counterparts. Importantly, Reolysin also significantly increased the antilymphoma activity of belinostat in HDAC inhibitor\u2013resistant cells. Our data demonstrate that Reolysin alone or in combination with belinostat is a novel therapeutic strategy to treat TCL patients who develop resistance to HDAC inhibitors.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002297","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T15:48:02Z","timestamp":1603813682000},"page":"5297-5310","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3885-1882","authenticated-orcid":false,"given":"Shariful","family":"Islam","sequence":"first","affiliation":[{"name":"Division of Translational and Regenerative Medicine, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia M.","family":"Espitia","sequence":"additional","affiliation":[{"name":"Division of Translational and Regenerative Medicine, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel O.","family":"Persky","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, The University of Arizona Cancer Center, Tucson, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Carew","sequence":"additional","affiliation":[{"name":"Division of Translational and Regenerative Medicine, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffan T.","family":"Nawrocki","sequence":"additional","affiliation":[{"name":"Division of Translational and Regenerative Medicine, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"issue":"1","key":"2020102711374032500_B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.canlet.2008.03.037","article-title":"Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy","volume":"269","author":"Carew","year":"2008","journal-title":"Cancer Lett"},{"issue":"19","key":"2020102711374032500_B2","doi-asserted-by":"crossref","first-page":"13548","DOI":"10.1074\/jbc.M510023200","article-title":"Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer","volume":"281","author":"Wilson","year":"2006","journal-title":"J Biol Chem"},{"issue":"20","key":"2020102711374032500_B3","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1158\/1078-0432.CCR-04-0455","article-title":"HDAC6 expression is correlated with better survival in breast cancer","volume":"10","author":"Zhang","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2020102711374032500_B4","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","article-title":"Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma","volume":"16","author":"Duvic","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"2020102711374032500_B5","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"issue":"12","key":"2020102711374032500_B6","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2020102711374032500_B7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors","volume":"10","author":"Grant","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"2020102711374032500_B8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/B978-0-12-394387-3.00002-1","article-title":"Mechanisms of resistance to histone deacetylase inhibitors","volume":"116","author":"Lee","year":"2012","journal-title":"Adv Cancer Res"},{"issue":"6","key":"2020102711374032500_B9","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1021\/mp200329f","article-title":"Histone deacetylase inhibitors: emerging mechanisms of resistance","volume":"8","author":"Robey","year":"2011","journal-title":"Mol Pharm"},{"issue":"2","key":"2020102711374032500_B10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ijc.2910550221","article-title":"Variable effects of sodium butyrate on the expression and function of the MDR1 (P-glycoprotein) gene in colon carcinoma cell lines","volume":"55","author":"Frommel","year":"1993","journal-title":"Int J Cancer"},{"issue":"30","key":"2020102711374032500_B11","doi-asserted-by":"crossref","first-page":"18031","DOI":"10.1016\/S0021-9258(19)84675-6","article-title":"Modulation of the expression of a multidrug resistance gene (mdr-1\/P-glycoprotein) by differentiating agents","volume":"264","author":"Mickley","year":"1989","journal-title":"J Biol Chem"},{"issue":"50","key":"2020102711374032500_B12","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1038\/sj.onc.1203176","article-title":"Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2\/Bcl-XL, c-Jun, and p21CIP1, but independent of p53","volume":"18","author":"Vrana","year":"1999","journal-title":"Oncogene"},{"issue":"9","key":"2020102711374032500_B13","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/ijc.25218","article-title":"Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance","volume":"127","author":"Shao","year":"2010","journal-title":"Int J Cancer"},{"issue":"4","key":"2020102711374032500_B14","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/leu.2008.1","article-title":"Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells","volume":"22","author":"Inoue","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"2020102711374032500_B15","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2007-10-116319","article-title":"Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells","volume":"112","author":"Fiskus","year":"2008","journal-title":"Blood"},{"issue":"21","key":"2020102711374032500_B16","doi-asserted-by":"crossref","first-page":"7706","DOI":"10.1158\/0008-5472.CAN-03-3897","article-title":"Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway","volume":"64","author":"Bandyopadhyay","year":"2004","journal-title":"Cancer Res"},{"issue":"4","key":"2020102711374032500_B17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3324\/haematol.2009.013870","article-title":"Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma","volume":"95","author":"Wozniak","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"2020102711374032500_B18","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.surg.2004.05.018","article-title":"Combined histone deacetylase and NF-\u03baB inhibition sensitizes non-small cell lung cancer to cell death","volume":"136","author":"Rundall","year":"2004","journal-title":"Surgery"},{"issue":"4","key":"2020102711374032500_B19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.bbrc.2005.11.131","article-title":"Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death","volume":"339","author":"Ozaki","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2020102711374032500_B20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ng.2913","article-title":"An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia","volume":"46","author":"Knoechel","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"2020102711374032500_B21","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1038\/ncomms10690","article-title":"Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells","volume":"7","author":"Ramirez","year":"2016","journal-title":"Nat Commun"},{"issue":"8","key":"2020102711374032500_B22","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/cncr.25741","article-title":"Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts","volume":"117","author":"Hingorani","year":"2011","journal-title":"Cancer"},{"issue":"5","key":"2020102711374032500_B23","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1158\/1535-7163.MCT-15-0695","article-title":"Strategic combinations: The future of oncolytic virotherapy with reovirus","volume":"15","author":"Zhao","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"5392","key":"2020102711374032500_B24","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1126\/science.282.5392.1332","article-title":"Reovirus therapy of tumors with activated Ras pathway","volume":"282","author":"Coffey","year":"1998","journal-title":"Science"},{"issue":"1","key":"2020102711374032500_B25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/leu.2017.272","article-title":"Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy","volume":"32","author":"Kelly","year":"2018","journal-title":"Leukemia"},{"issue":"25","key":"2020102711374032500_B26","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1038\/onc.2011.478","article-title":"Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma","volume":"31","author":"Kelly","year":"2012","journal-title":"Oncogene"},{"issue":"8","key":"2020102711374032500_B27","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/bloodadvances.2018026484","article-title":"Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity","volume":"3","author":"Carew","year":"2019","journal-title":"Blood Adv"},{"issue":"59","key":"2020102711374032500_B28","doi-asserted-by":"crossref","first-page":"100326","DOI":"10.18632\/oncotarget.22222","article-title":"Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy","volume":"8","author":"Islam","year":"2017","journal-title":"Oncotarget"},{"issue":"89","key":"2020102711374032500_B29","doi-asserted-by":"crossref","first-page":"35875","DOI":"10.18632\/oncotarget.26251","article-title":"Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC\/BCL2-addicted diffuse large B-cell lymphoma","volume":"9","author":"Islam","year":"2018","journal-title":"Oncotarget"},{"issue":"11","key":"2020102711374032500_B30","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1158\/1078-0432.CCR-16-1742","article-title":"Disruption of autophagic degradation with ROC-325 antagonizes renal cell carcinoma pathogenesis","volume":"23","author":"Carew","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"49","key":"2020102711374032500_B31","doi-asserted-by":"crossref","first-page":"86769","DOI":"10.18632\/oncotarget.21423","article-title":"Oncolytic reovirus inhibits angiogenesis through induction of CXCL10\/IP-10 and abrogation of HIF activity in soft tissue sarcomas","volume":"8","author":"Carew","year":"2017","journal-title":"Oncotarget"},{"issue":"24","key":"2020102711374032500_B32","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1101\/gad.1371305","article-title":"Global changes in STAT target selection and transcription regulation upon interferon treatments","volume":"19","author":"Hartman","year":"2005","journal-title":"Genes Dev"},{"issue":"10","key":"2020102711374032500_B33","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1158\/1535-7163.MCT-17-0089","article-title":"Disruption of aneuploidy and senescence induced by aurora inhibition promotes intrinsic apoptosis in double hit or double expressor diffuse large B-cell lymphomas","volume":"16","author":"Islam","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2020102711374032500_B34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0092-8674(01)00231-8","article-title":"Junction adhesion molecule is a receptor for reovirus","volume":"104","author":"Barton","year":"2001","journal-title":"Cell"},{"issue":"38","key":"2020102711374032500_B35","doi-asserted-by":"crossref","first-page":"41275","DOI":"10.18632\/oncotarget.5753","article-title":"Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus","volume":"6","author":"Kelly","year":"2015","journal-title":"Oncotarget"},{"issue":"25","key":"2020102711374032500_B36","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"issue":"130","key":"2020102711374032500_B37","first-page":"19","article-title":"STAT1 in cancer: friend or foe?","volume":"24","author":"Zhang","year":"2017","journal-title":"Discov Med"},{"issue":"3","key":"2020102711374032500_B38","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cellsig.2006.09.003","article-title":"STAT1 as a key modulator of cell death","volume":"19","author":"Kim","year":"2007","journal-title":"Cell Signal"},{"issue":"2","key":"2020102711374032500_B39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1172\/JCI16603","article-title":"The antitumor effects of IFN-\u03b1 are abrogated in a STAT1-deficient mouse","volume":"112","author":"Lesinski","year":"2003","journal-title":"J Clin Invest"},{"issue":"1","key":"2020102711374032500_B40","doi-asserted-by":"crossref","first-page":"R16","DOI":"10.1186\/bcr3100","article-title":"STAT1-deficient mice spontaneously develop estrogen receptor \u03b1-positive luminal mammary carcinomas","volume":"14","author":"Chan","year":"2012","journal-title":"Breast Cancer Res"},{"issue":"21","key":"2020102711374032500_B41","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-08-0524","article-title":"A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer","volume":"14","author":"Vidal","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2020102711374032500_B42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.mt.6300403","article-title":"A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas","volume":"16","author":"Forsyth","year":"2008","journal-title":"Mol Ther"},{"issue":"12","key":"2020102711374032500_B43","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1158\/0008-5472.CAN-09-4676","article-title":"Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signaling","volume":"70","author":"Shmulevitz","year":"2010","journal-title":"Cancer Res"},{"issue":"8","key":"2020102711374032500_B44","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1182\/blood-2010-09-305128","article-title":"High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS\/RAF\/MEK signaling cascade","volume":"117","author":"Kiessling","year":"2011","journal-title":"Blood"},{"issue":"29","key":"2020102711374032500_B45","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1038\/onc.2015.456","article-title":"Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency","volume":"35","author":"Ceccon","year":"2016","journal-title":"Oncogene"},{"issue":"5","key":"2020102711374032500_B46","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1158\/1535-7163.MCT-15-0240-T","article-title":"Histone deacetylase inhibitors enhance the therapeutic potential of reovirus in multiple myeloma","volume":"15","author":"Stiff","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2020102711374032500_B47","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood.V91.2.570","article-title":"Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression","volume":"91","author":"Sun","year":"1998","journal-title":"Blood"},{"issue":"4","key":"2020102711374032500_B48","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/13550280701344983","article-title":"JAK-STAT signaling pathways are activated in the brain following reovirus infection","volume":"13","author":"Goody","year":"2007","journal-title":"J Neurovirol"},{"issue":"7","key":"2020102711374032500_B49","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1038\/cddis.2013.259","article-title":"Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer","volume":"4","author":"Carew","year":"2013","journal-title":"Cell Death Dis"},{"issue":"22","key":"2020102711374032500_B50","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1158\/1078-0432.CCR-10-1233","article-title":"REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer","volume":"16","author":"Comins","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/20\/5297\/1779818\/advancesadv2020002297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/20\/5297\/1779818\/advancesadv2020002297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T21:14:51Z","timestamp":1618089291000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/20\/5297\/469752\/Resistance-to-histone-deacetylase-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":50,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2020,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002297","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]}}}